Clinical Outcomes Solutions (‘COS’), a global leader in the collection, analysis and reporting of patient-centred outcomes data with offices in Folkestone (UK), and Tucson and Chicago (USA), today marks five years of partnering collaboratively with FingerPost, a leading consultancy providing market-specific payer and Health Technology Assessment (HTA) insights and intelligence worldwide.
Established in 2013, COS is a global leader in delivering innovative science to capture and communicate the patient voice, in order to provide actionable evidence in clinical drug development through qualitative and quantitative research, with a specific focus on Clinical Outcomes Assessments.
FingerPost is a leader in market access and pricing strategy, providing the expertise and critical capabilities for pharmaceutical companies to optimise launch success.
This long-standing partnership supports COS projects by providing specific insights relating to Clinical Outcomes Assessment data used for stakeholder decision-making. For COS clients, the significant benefit is that they are fully informed to consider not only the regulatory requirements for their COA strategy, but also the payer and HTA landscape, thereby informing and bolstering market access and laying the foundations for success. Clients also benefit from a single point of contact throughout.
Having completed over 30 reviews together since 2016, this partnership has already proven highly successful. The powerful combination of subject matter experts specialising in COA strategy, pricing, market access and reimbursement ensures COS clients benefit from the flexibility, efficiency and expertise of two niche agencies operating with a defined and highly developed methodology.
Stacie Hudgens, Chief Executive Officer at COS, said: “This scientific partnership between COS and Fingerpost is the culmination of a long-standing relationship dedicated to informing the COA Competitive Landscape for our Sponsor clients in the anti-cancer therapy space. Our equal passion and dedication to including and understanding the patient voice in outcomes and clinical research has led to evidence synthesis that truly informs the COA strategy in new drug development.”
Catherine Bacon, Managing Director of FingerPost, said: “Our partnership with COS has proven highly successful in delivering in depth analyses of Health Technology Assessments (HTA) and the impact of patient-relevant outcomes on reimbursement recommendations and value-based /managed entry agreements across numerous therapeutic areas. The trend of including PRO data in HTA submissions is ever increasing, particularly in oncology, where there are greater expectations from payers to demonstrate the benefits of new therapies beyond overall survival. Our structured and collaborative approach means that clients get the regulatory and market access expertise of two niche agencies, through one contract and one point of contact.”
Tara Symonds, Chief Science Officer at COS, said: “Our partnership with FingerPost allows Sponsors access to an even greater level of expertise. The depth of insight that this brings to any COA landscape analysis results in industry leading COA strategies for our clients to utilise in leveraging maximum value to key stakeholders. Like COS, FingerPost has a global reach and, importantly, shares our commitment not only to innovative science, but also in putting the patient at the heart of everything we do.”